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Activation of genes containing SRE-1 (sterol regulatory element 1) sequences is known to be under the
regulation of sterols through modulation of the proteolytic maturation of SREBPs (SRE-1-binding proteins).
Previous work has demonstrated SREBP-mediated
transcriptional activation of genes encoding enzymes of
sterol and fatty acid biosynthesis. Because synthesis of
both sterols and C18 fatty acids are required for cell
growth, in the absence of exogenous supplements of
these lipids, we examined the hypothesis that fatty acid
can also be regulatory in SREBP maturation. Our data
indicate that C18 fatty acids can potentiate the biological activities of a typical, regulatory sterol: 25-hydroxycholesterol. Inhibition of C18 fatty acid synthesis in cells
cultured in serum-free medium renders them resistant
to killing by 25-hydroxycholesterol. Repression of expression of reporter constructs driven by promoters
bearing SRE-1 element(s) by 25-hydroxycholesterol is
increased by C18 fatty acid supplementation. C18 fatty
acids also increase the inhibitory effect of 25-hydroxycholesterol on proteolytic maturation and nuclear localization of SREBPs. Furthermore, we also show that C18
fatty acid supplementation can enhance the inhibitory
effect of 25-hydroxycholesterol on sterol and fatty acid
biosynthesis. These results demonstrate that maximal
down-regulation of SREBP maturation and the consequent repression of SRE-1 promoters occurs in response
to both a regulatory sterol and fatty acid.

Oxygenated sterols, such as 25-hydroxycholesterol, are
down-regulators of cholesterol biosynthesis (1). 25-Hydroxycholesterol down-regulates the rate-limiting step in this pathway, 3-hydroxy-3-methyl-glutaryl (HMG)1 coenzyme A reductase, through several mechanisms but also has a pleiotropic
effect on transcription of all the genes of the cholesterol biosynthetic pathway that have been studied to date (2). This
transcriptional control is mediated through the regulated two* The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
‡ To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, East Tennessee State University, James H.
Quillen College of Medicine, Box 70581, Johnson City, TN 37614-0581.
Tel.: 423-439-8367; Fax: 423-439-8366; E-mail: SINENSKY@ETSU.
EDU.
1
The abbreviations used are: HMG, 3-hydroxy-3-methyl-glutaryl;
SRE, sterol regulatory element; SREBP, sterol regulatory elementbinding protein; SCAP, SREBP cleavage-activating protein; CoA, coenzyme A; CHO, Chinese hamster ovary; FAF, fatty acid-free; BSA, bovine serum albumin; HDA, 2-hexadecynoic acid; PBS, phosphatebuffered saline; CAT, chloramphenicol acetyltransferase; LDL, low
density lipoprotein.

step proteolysis (3) of transcription factors called SREBPs,
which are synthesized as proteins localized to the endoplasmic
reticulum. SREBP proteolysis to the soluble, mature transcription factors is inhibited by 25-hydroxycholesterol at the first
cleavage. Genes that are transcriptionally activated by
SREBPs possess specific recognition elements for these proteins, called SREs (2). These include many of the genes of the
cholesterol biosynthetic pathway and the gene encoding the
LDL receptor (4). In addition, the genes encoding two of the
enzymes of fatty acid biosynthesis (4, 5) and HMG-CoA reductase (6) also contain sequences recognized by SREBPs that
differ from the classically defined SRE.
At least under some experimental conditions, it is possible to
demonstrate regulation of promoters for these genes encoding
enzymes of fatty acid biosynthesis, as well as those for cholesterol biosynthesis, by expression of SREBPs. Such studies,
utilizing promoter reporter constructs or measurement of
mRNA levels for specific enzymes of fatty acid biosynthesis,
have been performed both in cultured cells (4, 5, 7, 8) and
transgenic mice (7, 9) with truncated, soluble SREBP-1a and
SREBP-1c. However, these observations create something of a
metabolic paradox because they suggest that fatty acid biosynthesis can be inhibited by sterols, a regulatory mechanism that
would lead to inhibition of cell growth when exogenous sources
of sterols were high but fatty acids were poor.
Somatic cell mutants of CHO cells, resistant to killing by
25-hydroxycholesterol in the absence of lipoprotein cholesterol,
have been extremely useful in further defining the role of
SREBPs in the regulation of cholesterol biosynthesis (10, 11).
The mutants characterized to date, fall into two classes (3):
class 1 mutants are sterol-resistant because they produce a
truncated SREBP-2 that serves as a constitutive, mature transcription factor, and class 2 mutants are defective in a protein
called SCAP (SREBP-cleavage activating protein), which appears to transduce the oxysterol-mediated inhibition of SREBP
proteolysis. Class 2 mutants carry out the normally oxysterolregulated first proteolytic cleavage constitutively.
Many oxysterol-resistant mutants were isolated long before
the mechanism of transcriptional regulation of cholesterol biosynthesis, particularly the role of the SREs and SREBPs, was
understood. Early somatic cell genetic characterization indicated that there was genetic diversity in such mutants and that
some were recessive (13, 14). The class 1 and 2 mutants, whose
defects are now known, are dominant (or co-dominant) mutations. Our laboratory reported (15) a novel, recessive 25-hydroxycholesterol-resistant mutant (crB). This mutant had a
genetic defect in fatty acid elongation that was required for
both resistance to killing and down-regulation of mRNA levels
transcribed from cholesterol biosynthetic genes. Lack of regulation of the activity of the rate-limiting enzyme in cholesterol
synthesis, HMG-CoA reductase, as well as its mRNA, was
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observed. Supplementation of these cells with a mix of stearate
and oleate restored cell growth to normal, but most of the
regulation of HMG-CoA reductase by 25-hydroxycholesterol
and partial restoration of cell growth could be produced by
oleate supplementation alone. These results suggest a solution
to the metabolic paradox outlined above, which is that oxysterols can lose activity as regulators of SRE promoters when
cells are starved for C18 fatty acids, particularly oleate.
In this report we further explore the molecular basis for
these observations and test the hypothesis that oleate can
modulate the transcriptional regulatory activity of 25-hydroxycholesterol. The crB mutant turned out to be difficult to analyze
for such initial studies because, as will be described elsewhere,
its genotype appears to be complex. Instead, we have made use
of a potent inhibitor of fatty acid elongation, hexadecynoic acid,
in the current study.
EXPERIMENTAL PROCEDURES

Materials—IgG-2A4 and IgG-7D4 cells, which produce monoclonal
antibodies SREBP-1 and SREBP-2, respectively, were purchased from
American Type Culture Collection (catalog numbers CRL-2121 and
CRL-2198). All cell culture reagents were obtained from Life Technologies, Inc. Fatty acid-free bovine serum albumin (FAF-BSA, catalog
number A6003) was from Sigma. Stearate and oleate were obtained
from NuChek Prep (Elysian, MN), and 25-hydroxycholesterol was from
Steraloids Inc. (Wilton, NH). D-Threo-[dichloroacetyl-1,2-14C]chloramphenicol (catalog number NEC408A) was from NEN Life Science Products. Horseradish peroxidase-conjugated goat anti-mouse IgG was from
Pierce. The plasmids pLDLRCAT-6500 and pTK-Kx3-CAT were provided by Dr. David Russell (University of Texas, Dallas, TX). 2-Hexadecynoic acid (HDA) was a kind gift of Dr. J. M. Lowenstein (Brandeis
University, Waltham, MA).
Cell Culture and Transfection—CHO-K1 cells were grown in Ham’s
F12 medium containing 5% fetal calf serum, 100 mg/ml penicillin, and
100 mg/ml streptomycin (F12FC5) at 37 °C and 5% CO2. Stably transfected cells were produced by co-transfecting cells with 2 mg of pWLneo
and 20 mg of either pLDLRCAT-6500 or pTK-Kx3-CAT by the CaPO4
precipitation method using a mammalian transfection kit (Stratagene,
La Jolla, CA). The neomycin-resistant cells were selected using 600
mg/ml G418 (Life Technologies, Inc.) in F12FC5. Resistant colonies were
isolated and assayed for CAT activity as described below. Colonies
possessing CAT activity were expanded and maintained in F12FC5
containing 300 mg/ml G418. For 25-hydroxycholesterol cytotoxicity assays, CHO-K1cells were seeded at a density of 5,000 cells/60-mm dish in
F12FC5 on day 0. On day 1, the cells were rinsed with phosphatebuffered saline (PBS) twice and then fed either Nutridoma-SP (1% in
Ham’s F12) or Nutridoma-SP containing fatty acids and sterols as
described in the figure legends. Following a 48-h incubation, the Nutridoma-SP was removed, and the cells were fed F12FC5 for 5 days. The
surviving colonies were then fixed and stained with crystal violet as
described (13).
CAT Assay—For assay of chloramphenicol acetyltransferase (CAT),
cells were seeded in F12FC5 at 1.5 3 105 cells/well in multiwell (35 mm)
tissue culture plates (Falcon, catalog number 3846). Following a 16-h
incubation, the medium was removed, and the cells were rinsed twice
with PBS. The cells were then cultured for 16 h in F12 medium containing 5% twice-delipidized (15) fetal calf serum (F12DIPE5) in the
presence or absence of 1 mg/ml 25-hydroxycholesterol and supplemented with either 0.03% FAF-BSA or 10 mM stearate and 10 mM oleate
complexed to 0.03% FAF-BSA. The cells were rinsed twice with cold
PBS and once with cold 1 mM Tris-HCl, pH 7.5, 1 mM EGTA, and 1 mM
MgCl2 (buffer K) (16) before being incubated for 2 min in room temperature buffer K. The buffer K was aspirated, and cell lysate was collected
by scraping the cells in 200 ml of buffer K. The cell lysate was adjusted
to a concentration of 0.25 M Tris by the addition of an appropriate
amount of 2 M Tris-HCl, pH 7.5, and then clarified by centrifugation at
14,000 3 g at 4 °C for 5 min. 75 ml of 4 mM acetyl Co-A in 0.25 M Tris,
pH 7.5, was added to 50 ml of cell lysate, and the reactions were initiated
with 25 ml of 600 mM chloramphenicol containing 2 mCi/ml [14C]chloramphenicol in 0.25 M Tris, pH 7.5. Reactions were carried out at 37 °C
for 0.25 to 2 h before extraction of the chloramphenicol and reaction
products with 1 ml of ethyl acetate. After dessication, the residue was
resuspended in 50 ml of ethyl acetate and applied to LK5D silica TLC
plates (Whatman). The plates were developed in chloroform/methanol
(95:5). After drying, the TLC plates were subjected to autoradiography
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using Kodak XAR5 film. The amount of acetylated [ C]chloramphenicol produced was quantified by scintillation counting.
Cell Fractionation and Immunoblot Analysis—On day 0, cells were
seeded at 2 3 106/100-mm culture dish in F12FC5. On day 1, the
medium was removed, and the cells were rinsed twice with PBS. The
cells were then incubated for 20 h in F12DIPE5 containing 50 mM
compactin and 50 mM sodium mevalonate in the presence or absence of
sterols and fatty acids as described in the legends. Nuclear extracts and
105 3 g membrane fractions were prepared essentially as described by
Hua et al. (17). Protein concentration was determined using a mBCA kit
(Pierce). Samples of the nuclear extracts and membrane fractions were
mixed with 23 SDS loading buffer (18) and subjected to SDS-polyacrylamide gel electrophoresis on 7.5% gels. Following electrophoresis, the
proteins were transferred to Immobilon-P transfer membrane (Milipore). The blots were blocked with 5% nonfat dry milk in Tris-buffered
saline containing 0.05% Tween 20 (TBS-T) followed by a 1-h incubation
with either protein A-purified IgG-7D4 or IgG-2A4 at 5 mg/ml in TBS-T.
The blots were then rinsed five times with TBS-T and incubated for 1 h
with horseradish peroxidase-conjugated goat anti-mouse IgG diluted
1:50,000 in TBS-T. The blots were rinsed five times with TBS-T, and
ECL was performed using SuperSignal Chemiluminescent Substrate
kit according to the manufacturer’s instructions (Pierce).
Acetate Incorporation into Saponifiable and Nonsaponifiable Lipids—CHO-K1 cells were seeded at 1 3 106/100-mm culture dish in
F12FC5 for 16 h. The cells were rinsed with PBS twice and incubated
for 24 h in F12DIPE5 supplemented with 1 mg/ml 25-hydroxycholesterol and 50 mM oleate-BSA as indicated. [3H]Acetate (10 mCi/ml) was
added to each dish, and the incubation continued for another 24 h. Total
cellular lipids were extracted with hexane:isopropyl alcohol (60:40)
essentially as described previously (15). Lipids were saponified in 10%
methanolic KOH at 65 °C for 1 h, and nonsaponifiable lipids were
extracted into hexane. The aqueous phase was acidified with concentrated HCl, and the fatty acids were extracted into petroleum ether
followed by diethyl ether. Pooled extracts were dried under N2, and the
fatty acids were redissolved in hexane. Incorporation of [3H]acetate into
nonsaponifiable lipids and fatty acids was quantified by liquid scintillation counting. The protein concentration of each dish was determined
by solublizing the lipid extracted cells with 0.1 N NaOH and performing
a BCA protein assay (Pierce) using BSA as standard.
RESULTS

Effect of Inhibition of Fatty Acid Elongation on the Cytotoxicity of 25-Hydroxycholesterol—We have previously shown that
CHO-K1 cells treated with HDA, an inhibitor of endogenous
fatty acid elongation, synthesize very little stearate and no
detectable oleate compared with untreated controls (15). We
have also previously shown that a somatic cell mutant defective
in elongation of palmitate is resistant to the cytotoxic effects of
25-hydroxycholesterol in lipid-free medium (15).Therefore, we
reasoned that if C18 fatty acid synthesis was necessary for
25-hydroxycholesterol cytotoxicity, HDA treatment might
render cells resistant to 25-hydroxycholesterol. Indeed, when
CHO-K1 cells were incubated with HDA, the cytotoxicity of
25-hydroxycholesterol was diminished compared with cells not
treated with HDA (Fig. 1). HDA supplementation by itself was
without effect on the growth rate of the cells. These results
confirm our prior observations that C18 fatty acid synthesis
has a synergistic role in 25-hydroxycholesterol cytotoxicity.
Effect of Fatty Acid Supplementation on Sterol Regulation of
SRE Promoter-driven Transcription—Because inhibition of
C18 fatty acid synthesis with HDA renders CHO-K1 cells resistant to killing by 25-hydroxycholesterol in lipoprotein poor
medium, it seemed plausible that HDA treatment might also
produce resistance of genes containing SREs to down-regulation by 25-hydroxycholesterol, as well. This has been the general pattern observed with 25-hydroxycholesterol-resistant somatic cell mutants.
To determine whether cellular C18 fatty acid levels affect
sterol regulation, we examined the effects of HDA treatment
and fatty acid supplementation on transcription. For this, we
utilized an LDL receptor promoter construct, pLDLRCAT6500, which contains the entire LDL receptor promoter and has
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FIG. 1. Inhibition of fatty acid elongation in CHO-K1 cells reduces 25-hydroxycholesterol cytotoxicity. Cells were seeded at
1,000/60-mm culture dish in Ham’s F12 medium containing 5% fetal
calf serum (F12FC5) and incubated for 4 h. The culture medium was
then changed to Ham’s F12 medium containing 1% Nutridoma-SP and
either 0.5 mg/ml 25-hydroxycholesterol (25OH), 20 mm HDA complexed
to 0.03% FAF-BSA, or 25OH and HDA, as indicated to the right of the
figure. The medium for all cultures was adjusted to contain 0.03%
FAF-BSA and 0.05% ethanol (vehicle for 25-hydroxycholesterol). After
48 h the medium was removed, and the cells were rinsed and refed
F12FC5 for 96 h before being fixed and stained as described under
“Experimental Procedures.”

been demonstrated to be regulated by sterols (19). When stably
transfected into CHO-K1 cells, transcription of this construct is
up-regulated when incubated in delipidized medium and downregulated when the cells are treated with 25-hydroxycholesterol (Fig. 2). Supplementation of the delipidized medium with
fatty acids (stearate and oleate) complexed to FAF-BSA or with
FAF-BSA alone had little or no effect on the expression of the
reporter gene. However, when the delipidized medium was
supplemented with 25-hydroxycholesterol and fatty acids, expression of the reporter gene was reduced by approximately
2-fold compared with cells incubated in the same medium without fatty acids (Fig. 2). On the other hand, treatment of
CHO-K1 cells with HDA partially inhibited the down-regulation of the LDL receptor promoter by 25-hydroxycholesterol
(Fig. 2). HDA treatment caused a decrease in the down-regulation produced by 25-hydroxycholesterol from 7.2-fold to 2.5fold. Furthermore, the effect of HDA on the response to 25hydroxycholesterol could be nearly abolished by supplementing
the delipidized medium with 10 mM stearate and oleate. Supplementation of HDA-treated cells with these fatty acids resulted in an ;11-fold decrease in the amount of CAT activity
upon addition of 25-hydroxycholesterol, which is similar to the
amount of down-regulation produced by 25-hydroxycholesterol
in the absence of HDA. Thus, inhibition of fatty acid chain
elongation causes a diminuition in transcriptional regulation of
the LDL receptor promoter by 25-hydroxycholesterol.
We next examined whether the SRE-1 alone was sufficient to
confer fatty acid augmentation of sterol down-regulation or if
additional sequences outside of the SRE-1 were necessary for
this effect. For this we utilized an artificial promoter construct,
pTK-Kx3-CAT, which contains three tandemly repeated LDL
receptor SRE-1 sequences within the thymidine kinase promoter and has been shown to be regulated by sterols (20).
CHO-K1 cells stably transfected with pTK-Kx3-CAT showed a
response to 25-hydroxycholesterol similar to that of cells trans-

FIG. 2. Effect of C18 fatty acids on sterol regulation of transcription in CHO-K1 cells. Upper panel, CHO-K1 cells stably transfected with a CAT reporter gene driven by 26500 to 258 of the LDL
receptor promoter (pLDLRCAT-6500) were cultured for 16 h in Ham’s
F12 medium containing 5% organic solvent delipidized fetal calf serum
(F12DIPE5) supplemented with and without 1 mg/ml 25-hydroxycholesterol, 10 mg/ml cholesterol (Sterols) in the presence and absence of 10
mM stearate and 10 mM oleate (S.O.) as indicated. All fatty acids were
presented complexed to FAF-BSA, and the final concentration of the
culture medium was adjusted to contain 0.03% FAF-BSA and 0.35%
ethanol (solvent for 25-hydroxycholesterol and cholesterol). The cells
were then harvested and assayed for CAT activity as described under
“Experimental Procedures.” Lower panel, cells stably transfected with
pLDLRCAT-6500 were cultured under the same conditions described
for the upper panel except 20 mM HDA complexed to 0.03% FAF-BSA
was included in the medium. Values are the percentages of control 6
S.E.

FIG. 3. C18 fatty acids increase sterol regulation of transcription from an artificial promoter containing SRE-1. CHO-K1 cells
were stably transfected with pTK-Kx3-CAT, a CAT reporter gene
driven by an artificial promoter bearing three tandem repeats of the
LDL receptor SRE-1 inserted into the thymidine kinase promoter. Cells
were treated as described for the upper panel of Fig. 2.

fected with the full-length LDL receptor promoter construct
(Fig. 3). The sterol-mediated down-regulation of CAT activity
was further enhanced by C18 fatty acids. CHO-K1 cells stably
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FIG. 4. Oleate is sufficient for increasing sterol regulation of
the LDL receptor promoter in CHO-K1 cells. CHO-K1 cells stably
transfected with pLDLRCAT-6500 were incubated for 16 h in
F12DIPE5 supplemented with and without sterols and either 10 mM
stearate, 10 mM oleate, or 10 mM stearate plus 10 mM oleate as described
for the upper panel of Fig. 2.

FIG. 5. Effect of C18 fatty acids on sterol regulation of nuclear
SREBP-1 and SREBP-2 levels. Nuclear proteins were isolated from
CHO-K1 cells cultured for 24 h in F12DIPE5 in the presence or absence
of sterols (1 mg/ml 25-hydroxycholesterol and 10 mg/ml cholesterol) and
C18 fatty acids (10 mM stearate and 10 mM oleate (S.O.)) as indicated.
Samples of nuclear protein (50 mg) were subjected to electrophoresis on
denaturing SDS-polyacrylamide gels and transferred to polyvinylidene
difluoride membrane. Immunoblots were prepared using 5 mg/ml of a
monoclonal antibody to either SREBP-1 (IgG-2A4) or SREBP-2 (IgG7D4). The immunocomplexes were visualized by ECL. Films were exposed for 2 min.

transfected with a control construct lacking a SRE showed no
down-regulation when incubated in delipidized medium supplemented with 25-hydroxycholesterol alone or C18 fatty acids
and 25-hydroxycholesterol (data not shown; also see Ref. 20).
These results indicate that the SRE-1 element is the region of
the LDL receptor promoter that is responsible for the observed
effect of C18 fatty acids on the down-regulation of transcription
by 25-hydroxycholesterol. We also noted that most, if not all, of
the effect of the fatty acids on enhancing the down-regulatory
effects of 25-hydroxycholesterol on the LDL receptor promoter
could be observed with oleate supplementation alone (Fig. 4).
Effect of Fatty Acid Supplementation on the Nuclear Levels of
SREBP-1 and SREBP-2—Because regulation of LDL receptor
transcription by oxysterols via SRE-1 has been demonstrated
to be mediated by SREBPs, it seemed plausible that fatty acid
supplementation would enhance the lowering of nuclear
SREBP levels produced by 25-hydroxycholesterol. To test this
hypothesis, nuclear extracts were prepared from CHO-K1 cells
incubated in delipidized media supplemented with or without
fatty acids in the presence or absence of oxysterols. Aliquots of
nuclear extract were subjected to SDS-polyacrylamide gel electrophoresis and immunoblot analysis using monoclonal antibodies to SREBP-1 and SREBP-2. As expected, the nuclei of
cells cultured in the absence of sterols contained the mature
form of SREBP-1 and SREBP-2, whereas the nuclei of cells
incubated in medium supplemented with sterols contained significantly less of the mature form of either SREBP (Fig. 5).
Supplementation with fatty acids alone did not obviously alter
the nuclear levels of the mature SREBP-1 or BP-2. Consistent
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FIG. 6. C18 fatty acids enhance sterol inhibition of SREBP-1
and SREBP-2 proteolytic maturation. Nuclear and membrane proteins were isolated from CHO-K1 cells cultured for 24 h in F12DIPE5
containing 20 mM HDA and supplemented with and without sterols and
C18 fatty acids as described for Fig. 5. 100-mg samples of membrane
proteins (upper panels) and 50-mg samples of nuclear proteins (lower
panels) were analyzed by immunoblotting as described in the legend to
Fig. 5.

FIG. 7. Oleate supplementation potentiates the reduction of
nuclear SREBP-1 and SREBP-2 levels in response to sterols.
Nuclear proteins were prepared from CHO-K1 cells cultured for 24 h in
F12DIPE5 supplemented with and without sterols (1 mg/ml 25-hydroxycholesterol and 10 mg/ml cholesterol) and 10 mM stearate, 10 mM oleate,
or 10 mM stearate plus 10 mM oleate as indicated in the figure. Nuclear
protein samples (75 mg) were subjected to immunoblotting with monoclonal antibodies IgG-7D4 and IgG-2A4 as described in the legend to
Fig. 5.

with the results from the reporter constructs, incubation of
CHO-K1 cells with C18 fatty acids significantly enhanced the
activity of 25-hydroxycholesterol in lowering the levels of
SREBP-1 and BP-2 found in nuclear extracts. Because the
major reported mechanism regulating nuclear SREBP levels is
through sterol-mediated inhibition of their proteolytic maturation, these data are consistent with C18 fatty acids or a metabolite thereof, having a co-regulatory role in the proteolytic
processing of SREBPs in response to sterols. We found that the
effects of fatty acid supplementation on proteolytic processing
of SREBPs was most readily demonstrated in cultures in which
fatty acid elongation had been inhibited with HDA, where the
proteolytic processing is expected to be very efficient. The results of such an experiment (Fig. 6), confirms that C18 fatty
acid supplementation enhances the activity of 25-hydroxycholesterol in lowering nuclear SREBP levels. Furthermore, the
large decrease in the nuclear levels of the mature SREBPs in
cells treated with the combination of fatty acids and 25-hydroxycholesterol is accounted for by a large increase in the
accumulation of SREBP precursors in the membrane fractions.
This result is consistent with a co-regulatory effect of fatty acid
supplementation and 25-hydroxycholesterol on SREBP proteolytic maturation. Examination of stearate and oleate for specificity of regulation of nuclear SREBP levels indicates that the
regulatory response is specific for oleate (Fig. 7).
Regulation of Fatty Acid Synthesis in CHO-K1 Cells by 25Hydroxycholesterol and Fatty Acid Supplementation—The predicted metabolic consequences of the observed effects of 25hydroxycholesterol and fatty acids on SREBP processing would
be a differential regulation of fatty acid synthesis and sterol
synthesis by exogenous sterols and enhanced down-regulation
of both sterol and fatty acid synthesis by the combination of
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TABLE I
Incorporation of [3H]acetate into lipids of CHO-K1
Cells were seeded at 1 3 106/100-mm culture dish and incubated in F12FC5 for 24 h. The medium was changed to F12DIPE5 6 1.0 mg/ml
25-hydroxycholesterol (25OH) and 650 mm oleate complexed to 0.15% fatty acid free BSA for 16 h prior to the addition of [3H]acetate (10 mCi/ml).
Following a 24-h incubation, the incorporation into cellular lipids was determined as described under “Experimental Procedures.” The results are
the average of triplicate determination 6 S.D.
Lipid class

Control

25OH

Nonsaponifiable lipids
Fatty acids

120826 6 983
120866 6 2135

34619 6 1294
83612 6 5899

Oleate

25OH 1 Oleate

93273 6 5105
58721 6 6452

11740 6 647
32746 6 1866

dpm/h/mg protein

lipids. Differential regulation, presumably based on differential activity of residual mature SREBP in fatty acid starved
cells, would permit fatty acid synthesis to proceed under conditions where exogenous sources of sterol, but not fatty acids,
were present in sufficient quantity to permit cell growth. When
both lipids are present, it would be expected that both pathways would be significantly down-regulated.
To test these hypotheses, we examined the effect of 25hydroxycholesterol treatment on incorporation of labeled acetate into sterols (as nonsaponifiable lipid) and fatty acids (as
saponifiable lipid) in CHO-K1 cells in the presence or absence
of exogenous oleate. The results (Table I) indicate that treatment with 1 mg/ml 25-hydroxycholesterol, a condition that partially suppresses SREBP processing (Fig. 5) and suppresses
transcription from the LDL receptor promoter approximately
5-fold (Fig. 2), inhibits sterol synthesis approximately 3-fold,
whereas fatty acid synthesis is inhibited only 15%. Oleate
supplementation enhances the inhibition of both sterol and
fatty acid synthesis by 25-hydroxycholesterol.
DISCUSSION

Because fatty acids are precursors to membrane phospholipids, they constitute, along with cholesterol, the major structural constituents of the plasma membrane. It is therefore
plausible that the biosynthetic pathways for these membrane
components should be coordinately regulated. Several studies
have appeared (4, 5, 7, 8) demonstrating that sterols can be
regulatory for fatty acid synthesis through transcriptional control mediated by SREBP-1. A role for SREBP-1 in whole animal
fatty biosynthesis is also consistent with reduction in fatty acid
synthesis in liver of SREBP-1 knockout mice (21). These studies are good evidence for coordination of the cholesterol and
fatty acid biosynthetic pathways by sterols.
The opposite side of the cross-talk between fatty acid synthesis and cholesterol synthesis would be regulation of cholesterologenesis by fatty acids. Some suggestion that this can
occur was indicated in a prior study from our laboratory (15) of
a somatic cell mutant blocked in elongation of palmitate to
stearate, which was defective in down-regulation of mRNAs
encoding enzymes of sterol biosynthesis. We found that this
mutant required both stearate and oleate for optimal growth,
suggesting that cells could be sensitive to supplementation
with both fatty acids. In the course of these studies, we also
found that the regulatory responses to fatty acids could only be
observed in a basal medium that is scrupulously free of C18
fatty acids. The organic solvent delipidized serum supplements
or serum-free medium described above must be used to see
these effects. Many of the previously published studies on
regulation of SREBP processing by oxysterols have been performed in a basal medium with a lipopoprotein-deficient serum
supplement (see, for example, Ref. 17). Such medium still contains large amounts of fatty acids bound to serum albumin,
which would mask the fatty acid component of the response of
SREBP processing or LDL receptor promoter regulation to
oxysterol treatment that we describe in the current report.
In the current study, we demonstrate that oxysterol inhibi-

tion of proteolytic cleavage of SREBPs 1 and 2 is enhanced by
fatty acid supplementation. As expected, this co-regulation of
SREBP processing by 25-hydroxycholesterol and fatty acids
also manifests itself as co-regulation of SRE-1 driven transcription, sterol synthesis, and even 25-hydroxycholesterol cytoxicity. Consistent with such co-regulation, inhibition of endogenous fatty acid elongation with hexadecynoate has the opposite
effect of fatty acid supplementation on transcriptional repression by 25-hydroxycholesterol. The results with the individual
fatty acid supplements (Fig. 4), indicate that most, if not all, of
the co-regulatory effect on transcription is mediated by oleate.
This observation is consistent with a comparison of the effects
of stearate and oleate on SREBP processing (Fig. 7). We have
also previously noted that oleate supplementation can restore
most of the regulation of 3-hydroxy-3-methylglutaryl coenzyme
A reductase by 25-hydroxycholesterol in the crB mutant (15). It
is noteworthy that this restoration of regulation did not occur
either with saturated fatty acids (palmitate or stearate) or with
polyunsaturated fatty acids (linoleate or arachidonate).
Co-regulation of SREBP processing by sterol plus oleate is
mechanistically plausible in the light of our understanding of
the transcriptional control of the synthesis of these two lipids
by SREBPs. A class of regulatory somatic cell mutants, exemplified by M19, is defective in the second, oxysterol-insensitive,
proteolytic step of SREBP maturation (22). Significantly, these
mutants, which cannot form mature SREBPs, are auxotropic
for both cholesterol and oleate (23, 24). This is because of the
role of SREBPs in transcriptional activation, not only of genes
of the cholesterol biosynthetic pathway, but also the gene that
encodes the enzyme that converts stearate to oleate: stearoylCoA desaturase (9). A CHO-K1 mutant defective in stearoylCoA desaturase is an oleate auxotroph (25), demonstrating
that expression of this enzyme is required for oleate synthesis
and cell growth in the absence of exogenous oleate. Interestingly, the growth requirements for the mutants defective in
SREBP maturation, like M19, does not include stearate, despite the reported regulation of saturated fatty acid synthesis
by SREBPs, as well (4).
It therefore would appear that cholesterol and oleate constitute the two main metabolic products required for cell growth
whose biosynthesis is regulated by SREBPs. We hypothesize
that this dual requirement for these SREBP-regulated metabolites is responsible for presence of feedback regulation of
SREBP maturation by both of these lipid metabolic end products. This mechanism ensures that synthesis of oleate will
proceed in the presence of exogenous sterol, which in the absence of such bivalent control could down-regulate oleate synthesis producing a cellular growth arrest. We have demonstrated such a sparing effect on fatty acid synthesis in response
to 25-hydroxycholesterol treatment in Table I. Interestingly,
we also observe a statistically significant difference in the
extents of inhibition of fatty acid and sterol synthesis (t test:
0.02 , p , 0.01) in response to oleate treatment. This observation is consistent with a specific feedback regulation of fatty
acid synthesis, by fatty acids, in addition to the oxysterol/
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SREBP-mediated regulation. It has also been suggested that
regulation of fatty acid synthesis in whole animals by ADD1/
SREBP1, particularly in adipose tissue, is mediated primarily
by insulin (8).
It is entirely possible that a metabolite of oleate rather than
oleate itself is the second regulator. One possibility is the
intracellular form of cholesteryl ester, which is cholesterol
oleate (27). However, it does not seem likely that this compound is the regulator because acyl CoA:cholesteryl acyl transferase inhibitors have been reported to enhance rather than
inhibit down-regulation of LDL receptors (28) and HMG-CoA
reductase mRNA levels (28, 29) by exogenous sterol. There are,
of course, numerous other possibilities. For example, after activation of oleate to oleyl CoA, an important possible next step
in its metabolism is incorporation into the 2 position of lysophosphatidate to form phosphatidic acid. This reaction is catalyzed by an enzyme, monoacylglycerol phosphate acyltransferase, which is found on the cytosolic side of the endoplasmic
reticulum (30). This is the same localization as SCAP, which is
believed to be involved in sensing cellular sterols (31) through
its membrane attachment domain. Perhaps, the membrane
attachment domain of SCAP can sense such acyl-lipids as well
as sterols.
The differential response of SREBP maturation to saturated
and monounsaturated fatty acids is somewhat reminiscint of
nutritional studies on the effect of oleate-enriched diets on
serum cholesterol levels. Studies in both human subjects (32)
and monkeys (26) indicate when oleate is the major source of
dietary fat LDL, cholesterol levels are lowered and HDL cholesterol levels are raised. It has been observed (12) that human
subjects on oleate enriched-diets produce an oleate enriched
LDL that is more active than control LDL in lowering endogenous cholesterol synthesis. It is intriguing to speculate that
these physiological effects of dietary oleate might be correlated
with its down-regulatory effects on SREBP processing and
endogenous cholesterol synthesis.
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